The landscape of systemic therapy for early stage triple-negative breast cancer

被引：7

作者：

Lu, Jin-Yu ^{[1
]}

Soto, Alvaro Alvarez ^{[1
]}

Anampa, Jesus D. ^{[1
]}

机构：

[1] Montefiore Med Ctr, Albert Einstein Canc Ctr, Albert Einstein Coll Med, Dept Oncol,Sect Breast Med Oncol, Bronx, NY 10461 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2022年 / 23卷 / 11期

关键词：

Triple-negative breast cancer; systemic adjuvant therapy; immune checkpoint inhibitor; targeted therapy; chemotherapy; pathologic complete response; STANDARD NEOADJUVANT CHEMOTHERAPY; SURGICAL ADJUVANT BREAST; PHASE-III TRIAL; FOLLOW-UP; COMBINATION CHEMOTHERAPY; CAPECITABINE MAINTENANCE; DOSE-DENSE; CARBOPLATIN; DOXORUBICIN; SURVIVAL;

D O I：

10.1080/14656566.2022.2095902

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with higher risk of disease recurrence and mortality than other breast cancer subtypes. Historically, chemotherapy has been the primary systemic treatment for early stage TNBC. Recent developments in immune checkpoint inhibitors (ICIs) and novel therapeutic agents have transformed the treatment of TNBC. Areas covered: This review provides a comprehensive overview of the current evidence on treatment of early stage TNBC. We highlight the incorporation of ICIs and other targeted therapies in (neo) adjuvant treatment and the ongoing development of novel therapeutic agents. Expert opinion: The landscape of early TNBC treatment is rapidly evolving, which has given rise to the introduction of ICIs and PARP inhibitors into the systemic therapy. Despite modest improvement in the pathologic complete response (pCR) rate, ICI plus chemotherapy significantly improves long-term outcomes and is now used in (neo)adjuvant treatment of patients with TNBC and high risk for disease recurrence. Capecitabine remains the standard adjuvant treatment for residual disease, with olaparib being an option for patients with germline BRCA1/2 mutations. Early detection of minimal residual disease may identify patients requiring additional therapy to prevent recurrence.

引用

页码：1291 / 1303

页数：13

共 77 条

[1] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[2] Progress in adjuvant chemotherapy for breast cancer: an overview [J].

Anampa, Jesus ;

Makower, Della ;

Sparano, Joseph A. .

BMC MEDICINE, 2015, 13

[3] Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial [J].

Bardia, A. ;

Juric, D. ;

Shimizu, T. ;

Tolcher, A. ;

Karim, R. ;

Spira, A. ;

Mukohara, T. ;

Lisberg, A. E. ;

Kogawa, T. ;

Krop, I. ;

Papadopoulos, K. P. ;

Hamilton, E. ;

Damodaran, S. ;

Greenberg, J. ;

Gu, W. ;

Kobayashi, F. ;

Guevara, F. ;

Jikoh, T. ;

Kawasaki, Y. ;

Meric-Bernstam, F. .

ANNALS OF ONCOLOGY, 2021, 32 :S60-S60

[4] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[5] Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology) [J].

Blum, Joanne L. ;

Flynn, Patrick J. ;

Yothers, Greg ;

Asmar, Lina ;

Geyer, Charles E., Jr. ;

Jacobs, Samuel A. ;

Robert, Nicholas J. ;

Hopkins, Judith O. ;

O'Shaughnessy, Joyce A. ;

Dang, Chau T. ;

Gomez, Henry Leonidas ;

Fehrenbacher, Louis ;

Vukelja, Svetislava J. ;

Lyss, Alan P. ;

Paul, Devchand ;

Brufsky, Adam M. ;

Jeong, Jong-Hyeon ;

Colangelo, Linda H. ;

Swain, Sandra M. ;

Mamounas, Eleftherios P. ;

Jones, Stephen E. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) :2647-+

[6] Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials [J].

Boddington, C. ;

Bradley, R. ;

Braybrooke, J. ;

Burrett, J. ;

Clarke, M. ;

Davies, C. ;

Davies, L. ;

Dodwell, D. ;

Duane, F. ;

Evans, V. ;

Gettins, L. ;

Godwin, J. ;

Gray, R. ;

Hills, R. ;

James, S. ;

Liu, H. ;

Liu, Z. ;

MacKinnon, E. ;

Mannu, G. ;

McGale, P. ;

McHugh, T. ;

Morris, P. ;

Pan, H. ;

Peto, R. ;

Read, S. ;

Taylor, C. ;

Wang, Y. ;

Wang, Z. ;

Bradley, R. ;

Braybrooke, J. ;

Gray, R. ;

Bergh, J. ;

Peto, R. ;

Gray, Richard ;

Bradley, Rosie ;

Braybrooke, Jeremy ;

Liu, Zulian ;

Peto, Richard ;

Davies, Lucy ;

Dodwell, David ;

McGale, Paul ;

Pan, Hongchao ;

Taylor, Carolyn ;

Barlow, William ;

Bliss, Judith ;

Bruzzi, Paolo ;

Cameron, David ;

Fountzilas, George ;

Loibl, Sibylle ;

Mackey, John .

LANCET, 2019, 393 (10179) :1440-1452

[7] COMBINATION CHEMOTHERAPY AS AN ADJUVANT TREATMENT IN OPERABLE BREAST-CANCER [J].

BONADONNA, G ;

BRUSAMOLINO, E ;

VALAGUSSA, P ;

ROSSI, A ;

BRUGNATELLI, L ;

BRAMBILLA, C ;

DELENA, M ;

TANCINI, G ;

BAJETTA, E ;

MUSUMECI, R ;

VERONESI, U .

NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (08) :405-410

[8] Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer [J].

Burstein, Matthew D. ;

Tsimelzon, Anna ;

Poage, Graham M. ;

Coyington, Kyle R. ;

Contreras, Alejandro ;

Fuqua, Suzanne A. W. ;

Sayage, Michelle I. ;

Osborne, C. Kent ;

Hilsenbeck, Susan G. ;

Chang, Jenny C. ;

Mills, Gordon B. ;

Lau, Ching C. ;

Brown, Powel H. .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1688-1698

[9] Tissue-resident memory T cells in breast cancer control and immunotherapy responses [J].

Byrne, Ann ;

Savas, Peter ;

Sant, Sneha ;

Li, Ran ;

Virassamy, Balaji ;

Luen, Stephen J. ;

Beavis, Paul A. ;

Mackay, Laura K. ;

Neeson, Paul J. ;

Loi, Sherene .

NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (06) :341-348

[10] Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy [J].

Chen, Yu-Hsiang ;

Hancock, Bradley A. ;

Solzak, Jeffrey P. ;

Brinza, Dumitru ;

Scafe, Charles ;

Miller, Kathy D. ;

Radovich, Milan .

NPJ BREAST CANCER, 2017, 3

← 1 2 3 4 5 6 7 8 →